Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied by GlobalData

 in association with


Denmark Healthcare Market Bouncing Back After Recession

The Danish healthcare market is showing healthy signs of recovery following the crippling global financial crisis of 2008, says the latest report from business intelligence providers GlobalData.

The firm’s new report — Healthcare, Regulatory and Reimbursement Landscape - Denmark — predicts Denmark’s pharmaceuticals sector to grow from US$4 billion in 2011 to US$7.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 6.9%. This expected growth follows three years of shrinking pharmaceutical revenue for the north European country.

Additionally, Denmark’s medical devices sector is forecast to grow from 2011’s total of US$1.4 billion, to US$2.3 billion by the end of the decade.

GlobalData attributes Denmark’s healthcare industry expansion to a growing elderly population: 16.8% of Danish citizens were 65 years old or older in 2011, with this proportion reaching 19.6% by 2020, according to Statistics Denmark.

Additionally, Denmark’s pharmaceutical market will be bolstered by investment in innovative products. Novo Nordisk, along with other Danish firms such as LEO Pharma and Lundbeck, invest 15%–20% of their revenues in R&D. Furthermore, the country’s biotechnology sector spent approximately US$5.2 billion on R&D in 2011 – the second highest in Europe.

However, Denmark is not lacking in obstacles to overcome. At 25%, VAT in the country is higher than that of other countries in the EU (UK and the Netherlands have 20% and 19% respectively), and wages in Denmark are higher than all other nations in the Organization for Economic Co-operation and Development (OECD), with the exception of Norway. Consequently, manufacturing and sales costs are substantial in Denmark.

Healthcare, Regulatory and Reimbursement Landscape - Denmark

This report is an essential source of information and analysis on Denmark`s healthcare, regulatory and reimbursement landscape.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.


GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.


All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.



Free Sample Pages

Published: December 2012, Reference code: GDHC0031CHR

Report Price: $1995 (Single User License)


To top



To top